Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Rating of “Hold” from Analysts

Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) have been assigned a consensus rating of “Hold” from the seven research firms that are currently covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $22.25.

A number of brokerages have recently commented on ACRS. StockNews.com raised Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday. HC Wainwright restated a “neutral” rating on shares of Aclaris Therapeutics in a research note on Monday, July 22nd.

Aclaris Therapeutics Trading Up 3.0 %

Shares of Aclaris Therapeutics stock opened at $1.39 on Monday. The firm has a market capitalization of $99.05 million, a P/E ratio of -1.28 and a beta of 0.27. The business’s fifty day simple moving average is $1.18 and its 200 day simple moving average is $1.20. Aclaris Therapeutics has a 12 month low of $0.59 and a 12 month high of $10.15.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.04. Aclaris Therapeutics had a negative net margin of 248.28% and a negative return on equity of 61.03%. The company had revenue of $2.40 million for the quarter, compared to analysts’ expectations of $1.99 million. Analysts predict that Aclaris Therapeutics will post -0.77 EPS for the current fiscal year.

Insider Transactions at Aclaris Therapeutics

In related news, major shareholder Braden Michael Leonard bought 130,317 shares of Aclaris Therapeutics stock in a transaction on Thursday, July 18th. The stock was acquired at an average price of $1.30 per share, with a total value of $169,412.10. Following the acquisition, the insider now directly owns 13,578,286 shares of the company’s stock, valued at $17,651,771.80. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders purchased 2,435,393 shares of company stock valued at $2,750,797 over the last three months. Company insiders own 6.40% of the company’s stock.

Institutional Trading of Aclaris Therapeutics

A number of large investors have recently modified their holdings of the business. Vanguard Group Inc. raised its stake in Aclaris Therapeutics by 4.4% in the first quarter. Vanguard Group Inc. now owns 4,929,775 shares of the biotechnology company’s stock valued at $6,113,000 after purchasing an additional 207,418 shares in the last quarter. Russell Investments Group Ltd. raised its position in shares of Aclaris Therapeutics by 5,265.1% during the 1st quarter. Russell Investments Group Ltd. now owns 62,772 shares of the biotechnology company’s stock valued at $78,000 after buying an additional 61,602 shares in the last quarter. SG Americas Securities LLC lifted its holdings in shares of Aclaris Therapeutics by 69.5% during the 1st quarter. SG Americas Securities LLC now owns 32,843 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 13,461 shares during the last quarter. Marquette Asset Management LLC bought a new stake in shares of Aclaris Therapeutics during the 1st quarter worth $104,000. Finally, Deuterium Capital Management LLC bought a new position in Aclaris Therapeutics during the first quarter valued at approximately $99,000. Institutional investors own 98.34% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.